Group 1 - The article discusses the final results of a tender offer for common shares of Waqoo, Inc. [1]

Core Insights - Metaplanet's shares increased by approximately 7% following the announcement of a $130 million loan aimed at purchasing more Bitcoin [1] - Other digital asset treasury (DAT) firms also experienced share price increases, outperforming the broader Japanese equity market [1][2] - The Nikkei 225 index rose slightly over 1% during the same trading session [2] Company Performance - Remixpoint, which holds Bitcoin assets valued at around $128 million, saw a 22% increase in its share price [2] - SBC Medical Group Holdings' shares rose by about 5%, while Gumi's shares increased close to 3% [3] - Agile Media Network experienced a modest gain of approximately 1% [3] Market Reaction - The market reacted positively to Metaplanet's plans to accelerate Bitcoin purchases despite recent declines in digital asset prices [4] - Investor confidence in DATs appears to be waning, raising concerns about the sustainability of balance-sheet-driven strategies [5] Loan Details - Metaplanet's latest loan features a variable interest rate that resets daily, providing flexibility in response to borrowing cost changes [6] - This loan marks Metaplanet's second specifically for Bitcoin purchases, complementing a previously secured $500 million credit facility [7]

Core Insights - Metaplanet's shares increased by approximately 7% following the announcement of a $130 million loan aimed at purchasing more Bitcoin [1] - Other digital asset treasury firms (DATs) also experienced share price increases, surpassing the Nikkei 225 index, which rose just over 1% [1] - The market's positive reaction to Metaplanet's Bitcoin buying strategy comes despite recent declines in the crypto market [3] Company Developments - Metaplanet has taken a second loan for Bitcoin purchases, with a floating interest rate that renews daily, and the terms allow for debt repayment at any time [4] - The company previously established a $500 million credit facility to support its aggressive Bitcoin acquisition strategy [4] - Remixpoint, another firm in the sector, reported an 8.7% increase in share prices and holds Bitcoin valued at $128 million [2] Market Trends - Japanese firms are increasingly optimistic about crypto adoption, with major asset managers expressing interest in launching crypto funds [5] - Regulatory discussions are underway regarding the inclusion of crypto in mutual funds and potential tax reforms favorable to the crypto industry [6] - The share price growth of DATs outpaced Bitcoin's price increase of approximately 0.24% during the same period [2]

Financial Data and Key Metrics Changes - The company reported a steady increase in the number of franchisee clinics, reaching 258, with a 34-location increase, and the annual customer count expanded to approximately 6.5 million [2] - Financial performance showed signs of recovery, with sales previously affected by restructuring and franchise fee division, but now supported by an increase in point-related revenues [3][4] - The decline in racing-related costs, including share-based compensation expenses, contributed to improvements in both operating income and net income [3] Business Line Data and Key Metrics Changes - The average revenue per customer visit is showing signs of recovery due to pricing and promotion initiatives, as well as a multi-brand strategy in the dermatology segment [3] - The company is focusing on enhancing R&D and expanding service offerings through the acquisition of Waku, which specializes in regenerative medicine and skincare products [4][5] Market Data and Key Metrics Changes - The company has entered into a partnership with BLEZ ASIA to provide laser treatment in Thailand, aiming to tap into the growing aesthetic medical market [4] - The financial impact of the new BREATH initiative in Thailand is expected to be minimal in the near term as the company conducts proof of concept trials [10] Company Strategy and Development Direction - The company aims to strengthen its competitiveness and achieve sustainable growth through strategic acquisitions and partnerships, particularly in the aesthetic medical field [5][20] - The M&A strategy is divided into domestic and global perspectives, focusing on clinic acquisitions in Japan and exploring investments in the global market, especially in the US [20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about maintaining the positive momentum observed in Q3 2025, with expectations for stable financial performance in Q4 and 2026 [11][22] - The company is considering providing financial guidance in the near future to address investor needs for revenue and profit expectations [22][26] Other Important Information - The company is working on improving liquidity by increasing free float shares and considering new share issuances and share buybacks [24] - Dividend payments are being considered as a way to attract new investors, although the company prioritizes capital allocation towards strategic initiatives [25] Q&A Session Summary Question: Why was COVID elevated during Q3 2025, and when do you expect a franchise fee division impact to be fully absorbed going forward? - The increase in costs was attributed to medical equipment lease and the consolidation of AHH acquired in Singapore, with financial performance expected to continue improving [8] Question: Could you elaborate on the balance sheet changes during the quarter? - Changes included borrowing for working capital, adjustments in payment terms for related parties, and a decrease in tax debt due to midterm income tax payments [9] Question: What is your expectation for organic growth going forward for both breadth and revenue? - The company expects to maintain the positive momentum seen in Q3, with more stable financial performance anticipated in Q4 and next year [11] Question: Can you describe the strategic relationship behind acquiring Waku? - The acquisition aims to realize synergies through strengthening sales of Waku products at SBC clinics and jointly developing pharmaceutical and medical devices [12][14] Question: Can you comment on the latest status of your US business development efforts? - The company is in the phase of understanding the US market and seeking strong partners to leverage its strengths from Japan [17] Question: What do you mean by more stable financial performance in Q4 and 2026? - Management confirmed expectations for a return to revenue growth but could not provide specific numbers at this time [22] Question: How do you think about improving the liquidity situation? - The company aims to increase free float shares and is considering share buybacks due to the current low share price [24] Question: Do you have any plan to disclose financial guidance or performance guidance going forward? - The company is actively considering providing financial guidance in the near future [26]

Financial Data and Key Metrics Changes - Total revenue declined by 18% year on year due to strategic restructuring and increased point redemption by customers [5][6][21] - The elevated effective tax rate was primarily due to non-deductibility of some executive compensation and temporary timing differences in aircraft sales recognition [6][7] Business Line Data and Key Metrics Changes - The average customer spending is trending lower than last year, but there are early signs of recovery in certain areas such as the gorilla clinic [5][6] - The Jun clinic and Neo Skin clinic are achieving an average spend per customer that exceeds existing clinics, indicating strong growth potential [12][13] Market Data and Key Metrics Changes - The aesthetics medicine industry in Japan is experiencing severe competition, yet customer visits have increased to 6,310,000 annually, with a high repeat rate of 72% [4][5] - The dermatological aesthetics segment is showing a higher growth rate, presenting significant growth potential [10] Company Strategy and Development Direction - The company is implementing a multi-brand strategy tailored to different market segments to meet diverse customer needs [10][14] - The focus is on enhancing the medical tourism business, particularly targeting Chinese tourists [15] - The company aims to expand its clinic network from 260 to 1,000 clinics over the next ten years [32] Management's Comments on Operating Environment and Future Outlook - Management acknowledges that while there were negative factors impacting performance, they believe the business will improve moving forward [35][41] - The company is entering a phase of growth investment after completing business restructuring [44] Other Important Information - The company conducted its first-ever share buyback from May to July, which positively impacted share price and liquidity [22][44] - The company is considering new share issuance and partial sale by the founder to improve accessibility for a broader investor base [22][46] Q&A Session Summary Question: Are the new clinics starting up as planned? - Newly opened clinics are seeing steady customer visits, with an increase in male customers noted [24][25] Question: What is the future pricing trend? - The company is adopting a multi-brand strategy with different pricing tiers to meet varying customer needs [26] Question: Can you explain the growth strategy regarding organic and inorganic growth? - The company plans to proactively open new clinics and conduct M&A, with a strong track record of turning around acquired clinics [27][29] Question: How many clinics are you planning to open in Japan? - The company aims to increase the number of clinics to 1,000 over the next ten years [32] Question: What is the outlook for future profitability? - The company expects to secure sufficient margins and improve overall profitability as new clinics are established [34] Question: How is the company addressing the current share price trend? - The company is focusing on improving liquidity through share buybacks and considering dividend payments [43][44] Question: What are the plans for the CEO's shareholding? - The CEO is considering selling shares to improve liquidity and fund investments [46]